Previsão

Não temos dados de analistas para esta empresa.

Notícias Ir para o feed de notícias

ENvue Medical relocates NanoVibronix production entirely to the United States

ENvue Medical has completed the relocation of NanoVibronix manufacturing from Israel to the United States and now produces the entire product line in the U.S. Research and development activities remain consolidated in Tel Aviv. The company expects the consolidation to deliver lower operating costs, improved operational efficiency and optimized supply-chain management; affected devices include PainShield and UroShield. » Mais em de.investing.com
NanoVibronix reports quarterly loss per share of $6.88, revenue falls 36%

NanoVibronix released results for the quarter ended March 31, 2026: earnings per share were -$6.88 compared with -39,800 USD in the prior year. Revenue fell 36.27% to $0.7 million (prior year: $1.0 million). » Mais em finanzen.net
NanoVibronix rebrands as ENvue Medical and trades under FEED

NanoVibronix has changed its corporate name to ENvue Medical and is now listed on the Nasdaq Capital Market under the ticker symbol FEED. The company is strategically focused on its electromagnetic ENvue probe placement platform, which holds FDA 510(k) clearance for adults and is in use at 38 U.S. hospitals. NanoVibronix has a market capitalization of about $4.37 million, a current ratio of 0.86 and saw its share price fall 94% over the past year; it recently raised roughly $2 million in a registered direct offering and filed a new U.S. patent. Existing shareholders do not need to take any action, and the CUSIP number of the common stock remains unchanged. » Mais em de.investing.com

Dados financeiros da empresa

No último trimestre, NANOVIBRONIX DL-,001 registou receitas de € 209,41 mil e um ganho líquido de -€ 4,3 mi

(EUR)	junho de 2026	YoY
Receitas	209,41 mil	50,03%
Ganho bruto	-233,07 mil	684,89%
Ganho líquido	-4,3 mi	3.145,89%
EBITDA	-4,8 mi	66,22%

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 1,3 mi
Número de ações	796,92 mil
Máximo/mínimo de 52 semanas	€ 140,04 - € 0,90
Dividendos	Não
Beta	2,06
PER (PE Ratio)	0,00
PEG (PEG Ratio)	0,00
P/VC (PB Ratio)	0,06
P/V (PS Ratio)	1,47

Perfil da empresa

NanoVibronix, Inc. konzentriert sich über seine Tochtergesellschaft NanoVibronix Ltd. auf die Herstellung und den Verkauf von nicht-invasiven, biologische Reaktionen aktivierenden Geräten, die auf die Prävention von Biofilm, Wundheilung und Schmerztherapie abzielen. Zu den wichtigsten Produkten gehören UroShield, ein ultraschallbasiertes Produkt zur Verhinderung der bakteriellen Besiedlung und des Biofilms in Harnkathetern, zur Verbesserung der Wirksamkeit von Antibiotika und zur Verringerung von Schmerzen und Beschwerden im Zusammenhang mit der Verwendung von Harnkathetern; PainShield, eine pflasterbasierte therapeutische Ultraschalltechnologie zur Behandlung von Schmerzen, Muskelkrämpfen und Gelenkkontrakturen; und WoundShield, ein pflasterbasiertes therapeutisches Ultraschallgerät, das die Geweberegeneration und Wundheilung fördert. Das Unternehmen vertreibt seine Produkte direkt an Patienten sowie über Vertriebsvereinbarungen in den Vereinigten Staaten, Israel, Europa, Indien und international. NanoVibronix, Inc. wurde im Jahr 2003 gegründet und hat seinen Sitz in Elmsford, New York.

Nome	NANOVIBRONIX DL-,001
CEO	Doron Robert Besser
Sede	Elmsford, ny EUA
Site	nanovibronix.com
Setor	Indústria
Indústria	Serviços comerciais e fornecimentos
Entrada em bolsa	28/05/2015
Colaboradores	31